Boundless Bio, Inc.
Business
Boundless Bio is a clinical-stage oncology company developing small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) that target extrachromosomal DNA (ecDNA) amplification in cancer cells. The company's lead program, BBI-940, is a kinesin degrader in Phase 1 clinical development for ER+/HER2- breast cancer and triple-negative breast cancer. Boundless Bio operates through its proprietary Spyglass platform to identify targets essential for ecDNA function across multiple tumor types, with development focused on precision oncology for oncogene-amplified cancers in global markets.
Summary from 10-K filed 2026-03-09
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 45 | 55 | 43 | |
| General and administrative | 19 | 18 | 12 | |
| Total operating expenses | 64 | 73 | 55 | |
| Loss from operations | −64 | −73 | −55 | |
| Interest income | 5 | 8 | 5 | |
| Other income (expense), net | −2,000 | 12,000 | 80,000 | |
| Total other income, net | 5 | 8 | 5 | |
| Net loss | −58 | −65 | −49 | |
| Unrealized gain (loss) on short-term investments | −57,000 | 81,000 | 438,000 | |
| Comprehensive loss | −58 | −65 | −49 | |
| Net loss per share - basic | −2.6 | −3.85 | −40.65 | |
| Net loss per share - diluted | −2.6 | −3.85 | −40.65 | |
| Shares used in calculation, basic | 22 | 17 | 1 | |
| Shares used in calculation, diluted | 22 | 17 | 1 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 18 | 27 | 24 | |
| Short-term investments | 90 | 126 | 97 | |
| Prepaid expenses and other current assets | 2 | 2 | 3 | |
| Total current assets | 110 | 154 | 124 | |
| Property and equipment, net | 3 | 4 | 3 | |
| Right-of-use asset, net | 44 | 47 | 2 | |
| Restricted cash | 560,000 | 560,000 | 560,000 | |
| Other assets | 13,000 | 99,000 | 555,000 | |
| Total assets | 157 | 206 | 130 | |
| Accounts payable and accrued liabilities | 7 | 5 | 4 | |
| Accrued compensation | 3 | 3 | 3 | |
| Lease liabilities, current portion | 3 | — | 2 | |
| Total current liabilities | 13 | 8 | 9 | |
| Lease liabilities, non-current | 46 | 48 | — | |
| Total liabilities | 58 | 56 | 9 | |
| Commitments and contingencies (Notes 8) | — | — | — | |
| Preferred stock, $0.0001 par value; 70,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 700,000 shares authorized, 22,407 shares issued and outstanding as of December 31, 2025; 700,000 shares authorized, 22,300 shares issued and outstanding as of December 31, 2024 | 2,000 | 2,000 | 0 | |
| Additional paid-in-capital | 358 | 352 | 9 | |
| Accumulated other comprehensive income | 64,000 | 121,000 | 40,000 | |
| Accumulated deficit | −260 | −201 | −136 | |
| Total stockholders' equity | 99 | 151 | −127 | |
| Total liabilities and stockholders' equity | 157 | 206 | 130 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Stock-based compensation | 6 | 8 | 3 | |
| Depreciation and amortization | 1 | 1 | 957,000 | |
| Accretion of investments, net | −3 | −5 | −3 | |
| Non-cash lease expense | 3 | 3 | 2 | |
| Other | — | 102,000 | 25,000 | |
| Prepaid expenses and other assets | 332,000 | −302,000 | 85,000 | |
| Accounts payable and accrued liabilities | 2 | 775,000 | 2 | |
| Operating lease liabilities | 1 | −2 | −3 | |
| Net cash used in operating activities | −47 | −61 | −47 | |
| Purchases of investments | −175 | −208 | −160 | |
| Maturities of investments | 213 | 185 | 122 | |
| Purchases of property and equipment | −546,000 | −3 | −633,000 | |
| Net cash provided by (used in) investing activities | 38 | −26 | −38 | |
| Proceeds from the issuance of common stock from initial public offering, net of discounts | — | 93 | — | |
| Payments of common stock offering costs | — | −3 | — | |
| Proceeds from the exercise of stock options | — | 62,000 | 182,000 | |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 141,000 | 110,000 | — | |
| Net cash provided by financing activities | 141,000 | 90 | 98 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | −9 | 3 | 13 | |
| Change in unpaid common stock issuance costs | — | −197,000 | 197,000 | |
| Addition to right-of-use assets obtained in exchange for lease obligation | — | 48 | 282,000 | |
| Decrease to right-of-use assets due to remeasurement of lease obligation | −92,000 | — | −723,000 | |
| Vesting of early exercised stock options | — | 6,000 | 92,000 | |
| Unpaid property and equipment purchases | — | 400,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Boundless Bio, Inc.'s CIK number?
Boundless Bio, Inc.'s SEC CIK number is 0001782303 (1782303). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Boundless Bio, Inc.'s SEC filings?
All of Boundless Bio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Boundless Bio, Inc. last report earnings?
Boundless Bio, Inc. (BOLD) most recently filed an earnings 8-K with the SEC on May 8, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-213269). This is Boundless Bio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Boundless Bio, Inc.'s most recent earnings 8-K?
Boundless Bio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 8, 2026 under accession 0001193125-26-213269. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Boundless Bio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →